Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts

Cell Biology International

Volumn 35, Issue 2, 2011, Pages 93-98

  Dai, Hong Yan ^a   He, Tao ^a   Li, Xiao Lu ^b   Xu, Wen Liang ^a   Ge, Zhi Ming ^c  

^a QINGDAO MUNICIPAL HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Collagen; Extracellular signal regulated kinase1 2; Transforming growth factor b1; Urotensin 2

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UROTENSIN II;

ANIMAL CELL; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 78650154807     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090104     Document Type: Article

References (32)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.
2. Bohm F and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-7.
3. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA and Giaid A. Urotensin-I blockade with SB-11812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006;41:285-5.
4. Dai HY, Guo XG, Ge ZM, Li ZH, Yu XJ, Tang MX et al. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. J Diabetes Complications 2008;22:137-43.
5. Dai HY, Kang WQ, Wang X, Yu XJ, Li ZH, Tang MX et al. The involvement of transforming growth factor-beta1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept 2007;140:88-93.
6. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-87.
7. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-74.
8. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-7.
9. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-eta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-90.
10. Heimer R, Bashey RI, Kyle J, Jimenez SA. TGF-beta modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. J Mol Cell Cardiol 1995;27:2191-8.
11. Horstmeyer A, Licht C, Scherr G, Eckes B and Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. Febs J 2005;272:6297-309.
12. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004;370:238-50.
13. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressureoverloaded rats. Circulation 2002;106:130-5.
14. Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004;94:93-7.
15. Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003;144:1825-31.
16. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98:2765-73.
17. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-80.
18. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999;1:383-5.
19. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-54.
20. Qi JS, Minor LK, Smith C, Hu B, Yang J, Andrade-Gordon P et al. Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides 2005;26:683-90.
21. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001;37:827-32.
22. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-6.
23. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005;97:125-34.
24. Russell FD, Molenaar P, O'Brien, DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001;132:5-9.
25. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990;265:20555-62.
26. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima, Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003;72:1049-60.
27. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000;36:330-6.
28. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93:246-53.
29. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994;93:788-98.
30. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and rennin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
31. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 2002;16:64-8.
32. Ziltener P, Mueller C, Haenig B, Scherz MW, Nayler O. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J Recept Signal Transduct Res 2002;22:155-68.